Today: 9 June 2026
NuScale’s Stock Skyrockets on 6GW SMR Deal – Is GE Vernova Missing Out?
15 October 2025
3 mins read

NuScale’s Stock Skyrockets on 6GW SMR Deal – Is GE Vernova Missing Out?

  • NuScale SMR surges ~20%. NuScale Power’s ticker SMR jumped roughly 14% intraday on Oct. 13 and closed Oct. 15 around $55.09 – up 20.3% from the prior close ts2.tech Investing. The rally was driven by a historic SMR contract: NuScale’s partner ENTRA1 inked a 6 GW deployment program with TVA (six 77-MWe NuScale reactors) – “the largest SMR deployment in U.S. history” ts2.tech Wpln. This 6GW plan (powering ~4.5 million homes and dozens of AI data centers) sent SMR stock soaring.
  • Huge market growth. The global small modular reactor market is booming – from $5.81 billion in 2024 to a projected $8.37 billion by 2032. Utilities and tech firms (Google, Microsoft, OpenAI, etc.) are backing SMRs for reliable 24/7 power. For example, TVA signed deals for SMRs from both NuScale (TVA/ENTRA1) and Kairos Power, and even reactivated stalled projects (like Clinch River) Wpln ts2.tech. Europe is reviving nuclear too: Italy is moving to restart reactors “including modular and advanced” designs Nasdaq, and GE Vernova/Samsung announced five BWRX-300 SMRs for Sweden Nasdaq.
  • NuScale tech edge. NuScale’s SMR is the first and only U.S. design certified by the NRC – initially a 50-MWe unit in 2020, uprated to 77 MWe in May 2025 ts2.tech Wpln. NuScale’s factory-built modules can be stacked (up to 12 per plant, ~924 MWe total) ts2.tech. It has deep partnerships via ENTRA1 (financing and operating SMR plants), Standard Power (planning ~2 GW of SMRs for AI/data centers), and vendors like Paragon Energy (supply systems) ts2.tech ts2.tech. NuScale CEO John Hopkins calls the SMR “proven technology” that provides “clean, reliable, and, most importantly, safe” energy ts2.tech ts2.tech. Even Alphabet/Google’s CFO Ruth Porat has urged that “nuclear has to be a part of the mix” for future energy needs ts2.tech.
  • GE Vernova’s push. GE Vernova (GE’s nuclear arm, ticker GEV) is also racing to capture SMR demand with its BWRX-300 (300 MWe) reactor. In September, GE Vernova and Hitachi partnered with Samsung to sell BWRX-300s globally (five units proposed in Sweden) Nasdaq. TVA has formally accepted GE Vernova’s SMR application at Clinch River Nasdaq, with more projects expected. YTD GE Vernova stock is up ~97% (versus +151% for SMR) Nasdaq. However, GE Vernova’s legacy business faces headwinds: high tariffs and wind-unit costs are dragging profits Nasdaq. This led Zacks to rate GEV a weaker pick (Zacks Rank “Sell”) compared to SMR (“Hold”) Nasdaq.

Analysts Weigh In

Analysts note that SMR’s recent rally reflects both real progress and speculative fervor. On one hand, NuScale’s NRC approvals and partnerships set it up as an industry leader Finviz ts2.tech. In early October, NuScale shares even spiked +5% when Italy’s government moved to reintroduce nuclear power with “modular” reactors Nasdaq Nasdaq. On the other hand, NuScale still loses money (burning ~$95M cash per quarter as of mid-2025) and faces stiff competition Nasdaq Finviz. The Zacks report notes NuScale has underperformed peers recently (SMR +12.7% in 3 months vs. GE Vernova +17.6%, NanoNuclear +35%) Finviz. It warns that the energy market is competitive (especially with renewables) and that SMR’s valuation is stretched Finviz Finviz.

Indeed, metrics show SMR’s stock is expensive: a forward price/sales ratio ~85× Finviz (vs. ~4× for GEV Nasdaq) and a Zacks Value Score of F Finviz. Wall Street consensus reflects caution: out of ~15 analysts, most rate SMR a “Hold” or “Buy” with a median 12-month target around $37–$40 ts2.tech – roughly 25–30% below today’s $55 price. TradingView’s aggregate target is similar (~$42.75) ts2.tech. Zacks therefore assigns SMR a #3 (Hold) rating Finviz and suggests waiting for a pullback. By contrast, GE Vernova (Zacks #4 Sell) is seen as cheaper (P/S ~4.4×) but burdened by $300–$400M in 2025 tariffs and wind costs Nasdaq.

Outlook

Looking ahead, the analysts and industry experts are mostly bullish on SMR demand but mixed on the stocks. The NuScale/ENTRA1/TVA 6 GW deal provides a concrete project to support NuScale’s outlook, and similar global initiatives are emerging (Poland, Romania, Sweden, etc.). Tech companies and utilities are planning data centers and industrial hubs powered by SMRs ts2.tech ts2.tech. “Utilities see SMRs as crucial to provide round-the-clock carbon-free power in the AI era,” notes an industry analysis ts2.tech. NuScale plans its first plant by 2030 ts2.tech, and the U.S. government is funding many SMR projects, suggesting years of tailwinds.

However, execution risk remains high. Past SMR ventures have stumbled (NuScale’s 6-unit plant in Idaho was scrapped in 2023 after cost overruns Wpln). Delays and budget increases could damp stock gains. In the short term, if SMR stock retreats toward analyst targets (~$37–$40), some buyers may step in – but a sustained rally would require continued positive news (e.g. contract awards, regulatory wins). In sum, NuScale appears to lead the SMR boom ts2.tech, but investors should weigh its lofty valuation. As financial strategist Marcin Frąckiewicz notes, “NuScale’s SMR tech breakthroughs and key partnerships give it an edge,” but caution is warranted given high expectations Finviz.

Sources: News and analysis from Zacks, NASDAQ, TS2.tech, Motley Fool, WPLN, and company releases , stock quotes and data as of Oct. 14–15, 2025 .

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears
Previous Story

Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

MercadoLibre Stock Slides Amid Fintech Boom – Analysts Predict Big 2025 Comeback
Next Story

MercadoLibre Stock Slides Amid Fintech Boom – Analysts Predict Big 2025 Comeback

Go toTop